<?xml version="1.0" encoding="UTF-8"?>
<p>Camostat mesylate was first approved in Japan 2006 for the treatment of chronic pancreatitis due to its inhibitory effects on cholecystokinin, pro-inflammatory cytokines, and serine proteases in human. Based on their activities against TMPRSS2, camostat and a structurally related serine protease inhibitor, nafamostat are presently investigated as off-label administration in the treatment of SARS-CoV-2-infected patients
 <xref rid="CIT0056" ref-type="bibr">
  <sup>56â€“59</sup>
 </xref>.
</p>
